The predictive value of Atherogenic index of plasma and Clonal Hematopoiesis of Indeterminate Potential among Patients with STEMI---from a prospective cohort study

preprint OA: closed
Full text JSON View at publisher
AI-generated summary by claude@2026-07, 2026-07-15

In STEMI patients, clonal hematopoiesis of indeterminate potential (CHIP) combined with a high atherogenic index of plasma (AIP) significantly predicted increased all-cause mortality.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-15 · read from full text

This prospective cohort study evaluated the combined prognostic impact of clonal hematopoiesis of indeterminate potential (CHIP) and the atherogenic index of plasma (AIP) in 1,396 ACS patients undergoing primary percutaneous coronary intervention at Fuwai Hospital (2017–2020). Using deep targeted sequencing of 42 genes (median depth 14,219×), the authors found CHIP mutations (VAF ≥2%) in 14.5% of participants and reported that in patients with AIP ≥ the median, CHIP carriers had higher all-cause mortality (adjusted HR 2.22, 95% CI 1.24–3.98), with especially strong signals for TET2 mutations and TET2/ASXL1 co-mutations, while DNMT3A frameshift variants showed non-significant trends; they also noted that no association appeared among low-AIP patients. A key caveat explicitly stated by the preprint context is that it is not peer reviewed at the time of posting and that validation and mechanistic work are needed. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Acute coronary syndrome (ACS) remains a leading global cause of mortality despite advances in revascularization therapies. This prospective cohort study investigated the synergistic prognostic impact of clonal hematopoiesis of indeterminate potential (CHIP) and atherogenic index of plasma (AIP) in 1,396 ACS patients undergoing primary percutaneous coronary intervention at Fuwai Hospital (2017–2020). Using deep targeted sequencing (42 genes, median depth 14,219×), we identified CHIP mutations (VAF ≥ 2%) in 14.5% of participants, with DNMT3A (23.7%), TET2 (2.8%), and ASXL1 (1.9%) being most prevalent. High-AIP patients were younger (57.7 vs 63.1 years), had elevated hs-CRP (7.0 vs 6.0 mg/L), and higher smoking rates, suggesting accelerated atherosclerosis. Multivariable Cox regression revealed that in patients with AIP ≥ median, CHIP carriers exhibited significantly higher all-cause mortality (adjusted HR 2.22, 95% CI 1.24–3.98; p = 0.007), particularly for TET2 mutations (HR 6.37, CI 95%: 2.92–13.93; p<0.001) and TET2/ASXL1 co-mutations (HR 4.31, CI 95%: 2.13–8.74 ; p<0.001). Notably, DNMT3A frameshift variants showed non-significant mortality trends (HR 2.18, CI 95%: 0.65–7.38). Kaplan-Meier analyses confirmed the mortality risk stratification by AIP-CHIP interaction (log-rank p = 0.006), while no association emerged in low-AIP patients. These findings establish AIP as a critical modifier of CHIP-related cardiovascular risk, potentially through enhanced inflammatory pathways in younger ACS populations. The study highlights the clinical utility of combining lipid-based (AIP) and genetic (CHIP) biomarkers for precision prognostication, though validation in larger cohorts and mechanistic investigations of the AIP-CHIP interplay are warranted to guide targeted therapies.
Full text 17,489 characters · extracted from preprint-html · click to expand
The predictive value of Atherogenic index of plasma and Clonal Hematopoiesis of Indeterminate Potential among Patients with STEMI---from a prospective cohort study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The predictive value of Atherogenic index of plasma and Clonal Hematopoiesis of Indeterminate Potential among Patients with STEMI---from a prospective cohort study Xiaoxiao Zhao, Jiannan Li, Runzhen Chen, Yu Tan, Nan Li, Linghan Xue, and 7 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6685829/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 13 Aug, 2025 Read the published version in Cardiovascular Diabetology → Version 1 posted 9 You are reading this latest preprint version Abstract Acute coronary syndrome (ACS) remains a leading global cause of mortality despite advances in revascularization therapies. This prospective cohort study investigated the synergistic prognostic impact of clonal hematopoiesis of indeterminate potential (CHIP) and atherogenic index of plasma (AIP) in 1,396 ACS patients undergoing primary percutaneous coronary intervention at Fuwai Hospital (2017–2020). Using deep targeted sequencing (42 genes, median depth 14,219×), we identified CHIP mutations (VAF ≥ 2%) in 14.5% of participants, with DNMT3A (23.7%), TET2 (2.8%), and ASXL1 (1.9%) being most prevalent. High-AIP patients were younger (57.7 vs 63.1 years), had elevated hs-CRP (7.0 vs 6.0 mg/L), and higher smoking rates, suggesting accelerated atherosclerosis. Multivariable Cox regression revealed that in patients with AIP ≥ median, CHIP carriers exhibited significantly higher all-cause mortality (adjusted HR 2.22, 95% CI 1.24–3.98; p = 0.007), particularly for TET2 mutations (HR 6.37, CI 95%: 2.92–13.93; p<0.001) and TET2/ASXL1 co-mutations (HR 4.31, CI 95%: 2.13–8.74 ; p<0.001). Notably, DNMT3A frameshift variants showed non-significant mortality trends (HR 2.18, CI 95%: 0.65–7.38). Kaplan-Meier analyses confirmed the mortality risk stratification by AIP-CHIP interaction (log-rank p = 0.006), while no association emerged in low-AIP patients. These findings establish AIP as a critical modifier of CHIP-related cardiovascular risk, potentially through enhanced inflammatory pathways in younger ACS populations. The study highlights the clinical utility of combining lipid-based (AIP) and genetic (CHIP) biomarkers for precision prognostication, though validation in larger cohorts and mechanistic investigations of the AIP-CHIP interplay are warranted to guide targeted therapies. AIP clonal hematopoiesis of indeterminate potential ST-segment elevation myocardial infarction mortality Full Text Additional Declarations No competing interests reported. Supplementary Files supplement20250517.docx Cite Share Download PDF Status: Published Journal Publication published 13 Aug, 2025 Read the published version in Cardiovascular Diabetology → Version 1 posted Editorial decision: Revision requested 26 Jun, 2025 Reviews received at journal 26 Jun, 2025 Reviewers agreed at journal 05 Jun, 2025 Reviews received at journal 05 Jun, 2025 Reviewers agreed at journal 20 May, 2025 Reviewers invited by journal 20 May, 2025 Editor assigned by journal 17 May, 2025 Submission checks completed at journal 17 May, 2025 First submitted to journal 17 May, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6685829","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":459615056,"identity":"7b094145-6ad8-4568-aedc-c2ac7e23c1e0","order_by":0,"name":"Xiaoxiao Zhao","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Xiaoxiao","middleName":"","lastName":"Zhao","suffix":""},{"id":459615057,"identity":"c5e08302-2d32-426e-929e-db48240d2fc9","order_by":1,"name":"Jiannan Li","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Jiannan","middleName":"","lastName":"Li","suffix":""},{"id":459615058,"identity":"e5741813-f9ef-4374-b849-5b459d3efc8f","order_by":2,"name":"Runzhen Chen","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Runzhen","middleName":"","lastName":"Chen","suffix":""},{"id":459615059,"identity":"ece8fc83-6862-4300-802b-7641660992f0","order_by":3,"name":"Yu Tan","email":"","orcid":"","institution":"Central South University","correspondingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Tan","suffix":""},{"id":459615060,"identity":"c96cae48-0daa-4d7c-9093-5ea3f769af56","order_by":4,"name":"Nan Li","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Nan","middleName":"","lastName":"Li","suffix":""},{"id":459615061,"identity":"1168585b-61b8-4d3d-a543-4500accf90eb","order_by":5,"name":"Linghan Xue","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Linghan","middleName":"","lastName":"Xue","suffix":""},{"id":459615062,"identity":"dc978df2-434f-4efa-a6e0-a5154dbec80d","order_by":6,"name":"Shaodi Yan","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Shaodi","middleName":"","lastName":"Yan","suffix":""},{"id":459615063,"identity":"300c4f83-b262-41ff-b8b7-7ee9c36667dd","order_by":7,"name":"Chen Liu","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Chen","middleName":"","lastName":"Liu","suffix":""},{"id":459615064,"identity":"2b7377f2-ec32-4afe-a84d-264d9df06978","order_by":8,"name":"Peng Zhou","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Peng","middleName":"","lastName":"Zhou","suffix":""},{"id":459615065,"identity":"a2a65b45-d399-418a-8fcd-8336273fa83d","order_by":9,"name":"Yi Chen","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Chen","suffix":""},{"id":459615066,"identity":"b3539ddc-b414-4a68-a200-2c60306a107f","order_by":10,"name":"Hanjun Zhao","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Hanjun","middleName":"","lastName":"Zhao","suffix":""},{"id":459615067,"identity":"b9dda902-7487-4cac-ae52-6420b5fd7218","order_by":11,"name":"Li Song","email":"","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Li","middleName":"","lastName":"Song","suffix":""},{"id":459615068,"identity":"3212f110-7b45-4f49-8b69-eedda38ba8e1","order_by":12,"name":"Hongbing Yan","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAUlEQVRIiWNgGAWjYBACAwkQaQPEzMwHDiRU2PDw8zcQoyUNpIUt8cGDM2kykjMOEKuFgcfY8GHbYRuDhgT8Wsyleww/FyQcTuxvZzCTSDhznseA4QDjh485uLVYzjljLD0DqGXGYYY0iYSK2zzmzA3MkjO34XHYjRwDad4fh3MbDjMcA9pym8ey4QAbMy9+Lca/eRIO584/zNgmkdh2jsfgQAJBLWbSIC0bDjMzGyS2HSBCy51jZdY8Cen1Gw+zMT5IOJPMIznjYDN+v9xu3nybJ8HaWO78+Q8Hf1TY2fPzNx/88BGPFgYGDgN0EcYGfOqBgP0BAQWjYBSMglEw4gEAQaVZzqTiJ0IAAAAASUVORK5CYII=","orcid":"","institution":"Chinese Academy of Medical Sciences","correspondingAuthor":true,"prefix":"","firstName":"Hongbing","middleName":"","lastName":"Yan","suffix":""}],"badges":[],"createdAt":"2025-05-17 09:08:05","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6685829/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6685829/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12933-025-02877-4","type":"published","date":"2025-08-13T15:56:52+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":89310562,"identity":"496344b8-4952-4bc4-bc27-22366625c03e","added_by":"auto","created_at":"2025-08-18 16:08:02","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1416879,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript20250517.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6685829/v1_covered_2b017dd6-a651-4f94-acc7-0d9dc761be79.pdf"},{"id":83279441,"identity":"c47361f4-e56a-40d4-a659-ad2041db2401","added_by":"auto","created_at":"2025-05-22 10:02:30","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":103305,"visible":true,"origin":"","legend":"","description":"","filename":"supplement20250517.docx","url":"https://assets-eu.researchsquare.com/files/rs-6685829/v1/8da1e6e378004729b0d4dc2e.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"The predictive value of Atherogenic index of plasma and Clonal Hematopoiesis of Indeterminate Potential among Patients with STEMI---from a prospective cohort study","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"cardiovascular-diabetology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"cvdb","sideBox":"Learn more about [Cardiovascular Diabetology](http://cardiab.biomedcentral.com/)","snPcode":"12933","submissionUrl":"https://submission.nature.com/new-submission/12933/3","title":"Cardiovascular Diabetology","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"AIP, clonal hematopoiesis of indeterminate potential, ST-segment elevation myocardial infarction, mortality","lastPublishedDoi":"10.21203/rs.3.rs-6685829/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6685829/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAcute coronary syndrome (ACS) remains a leading global cause of mortality despite advances in revascularization therapies. This prospective cohort study investigated the synergistic prognostic impact of clonal hematopoiesis of indeterminate potential (CHIP) and atherogenic index of plasma (AIP) in 1,396 ACS patients undergoing primary percutaneous coronary intervention at Fuwai Hospital (2017\u0026ndash;2020). Using deep targeted sequencing (42 genes, median depth 14,219\u0026times;), we identified CHIP mutations (VAF\u0026thinsp;\u0026ge;\u0026thinsp;2%) in 14.5% of participants, with DNMT3A (23.7%), TET2 (2.8%), and ASXL1 (1.9%) being most prevalent. High-AIP patients were younger (57.7 vs 63.1 years), had elevated hs-CRP (7.0 vs 6.0 mg/L), and higher smoking rates, suggesting accelerated atherosclerosis. Multivariable Cox regression revealed that in patients with AIP\u0026thinsp;\u0026ge;\u0026thinsp;median, CHIP carriers exhibited significantly higher all-cause mortality (adjusted HR 2.22, 95% CI 1.24\u0026ndash;3.98; p\u0026thinsp;=\u0026thinsp;0.007), particularly for TET2 mutations (HR 6.37, CI 95%: 2.92\u0026ndash;13.93; p\u0026lt;0.001) and TET2/ASXL1 co-mutations (HR 4.31, CI 95%: 2.13\u0026ndash;8.74 ; p\u0026lt;0.001). Notably, DNMT3A frameshift variants showed non-significant mortality trends (HR 2.18, CI 95%: 0.65\u0026ndash;7.38). Kaplan-Meier analyses confirmed the mortality risk stratification by AIP-CHIP interaction (log-rank p\u0026thinsp;=\u0026thinsp;0.006), while no association emerged in low-AIP patients. These findings establish AIP as a critical modifier of CHIP-related cardiovascular risk, potentially through enhanced inflammatory pathways in younger ACS populations. The study highlights the clinical utility of combining lipid-based (AIP) and genetic (CHIP) biomarkers for precision prognostication, though validation in larger cohorts and mechanistic investigations of the AIP-CHIP interplay are warranted to guide targeted therapies.\u003c/p\u003e","manuscriptTitle":"The predictive value of Atherogenic index of plasma and Clonal Hematopoiesis of Indeterminate Potential among Patients with STEMI---from a prospective cohort study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-05-22 10:02:25","doi":"10.21203/rs.3.rs-6685829/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-06-26T15:58:29+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-06-26T15:44:05+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"270244992602099023489414522516894531217","date":"2025-06-05T15:37:42+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-06-05T14:31:42+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"336920270782493304837253446881442743666","date":"2025-05-20T17:55:40+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-05-20T14:24:01+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-05-17T15:40:21+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-05-17T14:05:09+00:00","index":"","fulltext":""},{"type":"submitted","content":"Cardiovascular Diabetology","date":"2025-05-17T08:52:37+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"cardiovascular-diabetology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"cvdb","sideBox":"Learn more about [Cardiovascular Diabetology](http://cardiab.biomedcentral.com/)","snPcode":"12933","submissionUrl":"https://submission.nature.com/new-submission/12933/3","title":"Cardiovascular Diabetology","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"06be8847-7b6f-491a-b647-fed4ea781da6","owner":[],"postedDate":"May 22nd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-08-18T16:01:52+00:00","versionOfRecord":{"articleIdentity":"rs-6685829","link":"https://doi.org/10.1186/s12933-025-02877-4","journal":{"identity":"cardiovascular-diabetology","isVorOnly":false,"title":"Cardiovascular Diabetology"},"publishedOn":"2025-08-13 15:56:52","publishedOnDateReadable":"August 13th, 2025"},"versionCreatedAt":"2025-05-22 10:02:25","video":"","vorDoi":"10.1186/s12933-025-02877-4","vorDoiUrl":"https://doi.org/10.1186/s12933-025-02877-4","workflowStages":[]},"version":"v1","identity":"rs-6685829","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6685829","identity":"rs-6685829","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00